Tealwood Asset Management Inc. Has $1.14 Million Stake in Allergan plc (AGN)

Tealwood Asset Management Inc. cut its stake in shares of Allergan plc (NYSE:AGN) by 8.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,975 shares of the company’s stock after selling 608 shares during the period. Tealwood Asset Management Inc.’s holdings in Allergan were worth $1,141,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pathstone Family Office LLC lifted its stake in Allergan by 3,327.3% in the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after acquiring an additional 366 shares during the last quarter. Howard Hughes Medical Institute acquired a new stake in Allergan in the second quarter valued at approximately $103,000. Massey Quick & Co. LLC lifted its stake in Allergan by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after acquiring an additional 385 shares during the last quarter. Cable Hill Partners LLC lifted its stake in Allergan by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares during the last quarter. Finally, Pacific Center for Financial Services lifted its stake in Allergan by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after acquiring an additional 7 shares during the last quarter. 80.23% of the stock is currently owned by hedge funds and other institutional investors.

AGN has been the subject of a number of analyst reports. Argus cut shares of Allergan from a “buy” rating to a “hold” rating and reduced their target price for the company from $256.80 to $160.07 in a research note on Thursday, December 7th. JPMorgan Chase & Co. set a $275.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Sunday, October 22nd. Deutsche Bank reiterated a “buy” rating and issued a $215.00 target price on shares of Allergan in a research note on Tuesday, January 9th. Zacks Investment Research cut shares of Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Vetr cut shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 target price for the company. in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $227.23.

Shares of Allergan plc (NYSE:AGN) traded down $1.43 during trading on Friday, hitting $162.77. 4,233,822 shares of the stock were exchanged, compared to its average volume of 3,070,000. The firm has a market capitalization of $54,130.00, a PE ratio of -13.58, a price-to-earnings-growth ratio of 1.17 and a beta of 1.19. Allergan plc has a twelve month low of $157.70 and a twelve month high of $256.80. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.90 EPS. equities research analysts anticipate that Allergan plc will post 15.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.77%. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is -23.35%.

In other Allergan news, insider William Meury sold 11,807 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Brent L. Saunders purchased 4,600 shares of the stock in a transaction on Wednesday, December 6th. The stock was acquired at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders acquired a total of 17,630 shares of company stock worth $2,890,057 in the last three months. Insiders own 0.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Tealwood Asset Management Inc. Has $1.14 Million Stake in Allergan plc (AGN)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/02/12/tealwood-asset-management-inc-sells-608-shares-of-allergan-plc-agn.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply